22:05 on September 29, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock changed, and the share price quickly rose 6.15%. As of press time, the stock was trading at US $0.518 per share, with a turnover rate of 0.005% and an amplitude of 0.005%.
Recent earnings data show that the stock achieved operating income of $2362.00, net profit of-$281603.00, earnings per share of-$0.010, gross profit of $419.00, and price-to-earnings ratio of-63.17 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry in which WUHAN GENERAL GP's shares are located in the US OTC market, the overall increase is 1.05 per cent. Among its related stocksPetros Pharmaceuticals Inc、Clarus Therapeutics Hldgs Inc C/Wts 11 + 08 * 2026 (To Pur Com)、REGENCELL BIOSCIENCE HLDGS LTDThe increase is relatively large.Sonoma Pharmaceuticals Inc、Teligent Inc New、Tilray IncRelatively active, with turnover rates of 25.22%, 0.87% and 0.82%, respectively. The related stocks with larger amplitudes areCumberland Pharmaceutical Co., Ltd.、Alpha Teknova, Inc.、Evoke Pharma IncThe amplitudes were 9.29%, 7.02% and 6.87%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
At the news level, as of 22:05, WUHAN GENERAL GP (WUHN.us) shares in the US OTC market accounted for 100 per cent of positive public opinion news.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )